Academic Highlights: A Roadmap to Key Pharmacologic Principles in Using Antipsychotics in the Treatment of Bipolar Disorder
J Clin Psychiatry 2008;69(7):1176-1183
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
On the basis of the National
Comorbidity Survey Replication
(NCS-R), it is estimated that bipolar I
and II disorders may affect nearly 3%
of the population (i.e., 5.7 million
Americans), with the prevalence of
subthreshold but still impairing bipolar
presentations estimated to be even
higher. Bipolar disorder is associated
with significant functional impairment
and elevated health care costs. Although
unipolar depression appears to
be over 6 times as prevalent as bipolar
disorder, NCS-R data found that the
costs of bipolar disorder to the U.S.
workplace, estimated at $14.1 billion
annually, were almost half the cost of
lost productivity associated with unipolar